Streetbeat News

Analyst Ratings

MRK

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Merck & Co (NYSE:MRK) and maintained a price target of $155.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:12 pm

VRNA

Verona Pharma shares rose after Wells Fargo initiated coverage with an Overweight rating and a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:04 pm

RCUS

Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Arcus Biosciences (NYSE:RCUS).

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:02 pm

RPM

Analysts have mixed ratings on RPM International (NYSE:RPM) with a slight positive shift in price targets. The average 12-month price target increased by 1.55% to $125.67. RPM faces revenue challenges but shows strong profitability and financial health.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 3:02 pm

OSTX

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for OS Therapies (AMEX:OSTX) and maintained a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:01 pm

LRMR

Larimar Therapeutics shares rose after Wedbush initiated coverage with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:01 pm

PFE

In the past three months, 11 analysts have rated Pfizer (NYSE:PFE), with most being somewhat bullish. The average 12-month price target increased by 3.13% to $38.82. Analysts' ratings reflect their reactions to market conditions and Pfizer's performance. Despite Pfizer's strong market presence, it faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 3:01 pm

JBLU

JetBlue Airways (NASDAQ:JBLU) has received mixed analyst ratings over the past three months, with all seven analysts rating it as 'Indifferent'. The average 12-month price target has increased by 12.66% to $5.43. Analysts have adjusted their price targets, reflecting dynamic market conditions and company performance. JetBlue faces financial challenges, including a decline in revenue growth, low net margin, and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 3:01 pm

KMX

CarMax (NYSE:KMX) has received mixed analyst ratings over the past three months, with a slight increase in the average 12-month price target. Analysts have varied in their recommendations, with some raising and others lowering their price targets. CarMax faces revenue challenges but maintains strong net margins and effective asset utilization.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 3:01 pm

HUBG

Hub Group (NASDAQ:HUBG) has received mixed analyst ratings over the past three months, with a majority being indifferent. The average 12-month price target has increased slightly to $46.1. Despite a decline in revenue growth, Hub Group shows strong profitability with a high net margin and effective debt management.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 3:00 pm